- Home
- JYD vs APM Comparison
JYD vs APM Comparison
Compare JYD & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JYD | APM |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.3M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | JYD | APM |
|---|---|---|
| Price | $0.77 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 346.9K | 255.6K |
| Earning Date | 05-15-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.65 |
| 52 Week High | $6.85 | $4.47 |
Technical Indicators
Market Signals| Indicator | JYD | APM |
|---|---|---|
| Relative Strength Index (RSI) | 29.70 | 43.86 |
| Support Level | $0.54 | $0.74 |
| Resistance Level | $1.07 | $0.93 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 16.09 | 3.81 |
Price Performance
Historical ComparisonAbout JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, fragmented logistics, and chartered airline freight services, supply chain management, and other value-added services.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.